A new stability indicating RP-HPLC method for estimation of Osimertinib Mesylate
A simple stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of Osimertinib Mesylate in tablet dosage forms. Reversed-phase chromatography was performed on Shimadzu Model CBM-20A/20 Alite, using a mixture of 0.1% T.E.A and methanol (50:50, v/v) as mobile phase with a flow rate of 1.0 mL/min. Detection was carried at 211nm. Linearity was observed over the concentration range of 10–400 μg/mL (R2 = 0.9992) with regression equation y = 125927x + 192648 Osimertinib Mesylate was subjected to stress conditions (acidic, alkaline, oxidation and thermal degradation) and validated as per ICH guidelines. The validated method can be applied to perform long-term and accelerated stability studies of Osimertinib Mesylate formulations.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).